Enlivex Reports Positive Data in Knee Osteoarthritis Study
Immunotherapy company, Enlivex Therapeutics (Nasdaq: ENLV), has released positive data from its Phase 1/2 investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis. The study’s three-month data showed a significant reduction in pain and a favorable safety profile.
The AllocetraTM injection was successful in patients with severe osteoarthritis of the knee that had attempted multiple other treatments with no lasting improvement. The injection potentially offers a better treatment option to replace or delay progression to extensive surgery.
Einat Galamidi, M.D., Vice President, Medical of Enlivex, said, “After a robust experience with systemic infusions of AllocetraTM across multiple clinical studies, this is the first report of clinical outcomes following a focused AllocetraTM injection to the joint. We believe that the results confirm the safety of AllocetraTM in the local setting and pave the way to further explore the potential therapeutic utilization of AllocetraTM in joint diseases with inflammatory involvement.”
Results of the study included pain reduction of 64% from baseline, 33% of patients reported complete pain resolution, and 89% of patients did not proceed with knee replacement surgery at three months post-injection.
Osteoarthritis is the most common form of arthritis, affecting more than 32.5 million Americans and more than 300 million individuals worldwide. 78 million Americans are projected to have osteoarthritis by the year 2040.
About Enlivex
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.
